Cardiovascular molecular MR imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 1 SUPPL., 2007, Pages

  Lamb, H J ^a   Van Der Meer, R W ^a   De Roos, A ^a   Bax, J J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Cardiovascular molecular imaging; Contrast agents; MR spectroscopy

Indexed keywords

ADENOSINE; DIPYRIDAMOLE; FIBRIN; GADOLINIUM; IRON OXIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

CARDIOVASCULAR DISEASE; DIAGNOSTIC IMAGING; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW;

APOPTOSIS; CARDIOVASCULAR DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR PROBE TECHNIQUES; MYOCARDIUM;

EID: 34250700986     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0444-z     Document Type: Review

References (14)

1. Jaffer FA, Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ Res 2004;94 4:433-45.
2. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003;42 2:328-35.
3. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 2006;114:1151-8.
4. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. PNAS 2005;102;808-13.
5. 23Na magnetic resonance imaging. Circulation 2004;110:3457-64.
6. Ouwerkerk R, Weiss RG, Bottomley PA. Measuring human cardiac tissue sodium concentrations using surface coils, adiabatic excitation, and twisted projection imaging with minimal T2 losses. J Magn Reson Imaging 2005;21:546-55.
7. Bottomley PA, Weiss RG. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 1998;351:714-8.
8. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003;49:417-23.
9. Lima JAC, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J Am Coll Cardiol 2004;44:1164-71.
10. Baer FM, Theissen P, Schneider CA, Voth E, Sechtem U, Schicha H, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998;31 5:1040-8.
11. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343 20:1445-53.
12. Bulte JW, Kraitchman D. Iron oxide MR contrast agents for molecular and cellular imaging. NMR in Biomedicine 2004;17:484-99.
13. Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC Jr, Botnar RM, et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 2005;111 11:1377-82.
14. Spuentrup E, Fausten B, Kinzel S, Wiethoff AJ, Botnar RM, Graham PB, et al. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation 2005;112 3:396-9.